StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
Shares of GLMD opened at $0.39 on Wednesday. The firm has a fifty day simple moving average of $0.36 and a two-hundred day simple moving average of $0.38. Galmed Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $7.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- MarketBeat Week in Review – 4/22 – 4/26
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is a buyback in stocks? A comprehensive guide for investors
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
